Sulfamides as novel histone deacetylase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 2, 2009, Pages 336-340

  Wahhab, Amal ^a   Smil, David ^a   Ajamian, Alain ^a   Allan, Martin ^a   Chantigny, Yves ^a   Therrien, Eric ^a   Nguyen, Natalie ^a   Manku, Sukhdev ^a   Leit, Silvana ^a   Rahil, Jubrail ^a   Petschner, Andrea J ^a   Lu, Ai Hua ^a   Nicolescu, Alina ^a   Lefebvre, Sylvain ^a   Montcalm, Samuel ^a   Fournel, Marielle ^a   Yan, Theresa P ^a   Li, Zuomei ^a   Besterman, Jeffrey M ^a   Déziel, Robert ^a  

^a METHYLGENE INC   (Canada)

Author keywords

HDAC inhibitors; HDAC1; HDAC6; Sulfamide

Indexed keywords

APICIDIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; LYSINE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; SCAFFOLD PROTEIN; SULFAMIDE DERIVATIVE; THIOL; TRIFLUOROMETHYLKETONE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PHARMACOPHORE; REACTION ANALYSIS;

AMIDES; ENZYME INHIBITORS; HISTONE DEACETYLASES;

EID: 57749208364     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.081     Document Type: Article

References (45)

1. Hildmann C., Riester D., and Schwienhorst A. Appl. Microbiol. Biotechnol. 75 (2007) 487
2. De Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., and van Kuilenburg A.B. Biochem. J. 370 (2003) 737
3. Voelter-Mahlknecht S., Ho A.D., and Mahlknecht U. Int. J. Mol. Med. 16 (2005) 589
4. Kim Y.B., Lee K.-H., Sugita K., Yoshida M., and Horinouchi S. Oncogene 18 (1999) 2461
5. Jung M., Hoffmann K., Brosch G., and Loidl P. Bioorg. Med. Chem. 7 (1997) 1655
6. Grant S., Easley C., and Kirkpatrick P. Nat. Rev. Drug Discov. 6 (2007) 21
7. Paris M., Porcelloni M., Binaschi M., and Fattori D.J. Med. Chem. 51 (2008) 1505
8. Bieliauskas A.V., and Pflum M.K.H. Chem. Soc. Rev. 37 (2008) 1402
9. Bruserud O., Stapnes C., Ersvaer E., Gjertsen B.T., and Ryningen A. Curr. Pharm. Biotechnol. 8 (2007) 388
10. Moradei O., Maroun C.R., Paquin I., and Vaisburg A. Curr. Med. Chem. Anti-Cancer Agents 5 (2005) 529
11. tenHolte P., Van Emelen K., Janicot M., Fong P.C., de Bono J.S., and Arts J. Top. Med. Chem. 1 (2007) 293
12. Chen J.S., Faller D.V., and Spanjaard R.A. Curr. Cancer Drug Targets 3 (2003) 219
13. Maiso P., Carvajal-Vergara X., Ocio E.M., Lopez-Perez R., Mateo G., Gutierrez N., Atadja P., Pandiella A., and San Miguel J.F. Cancer Res. 66 (2006) 5781
14. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., La Thangue N.B., and Brown R. Mol. Cancer Ther. 2 (2003) 721
15. Zhou N., Moradei O., Raeppel S., Leit S., Fréchette S., Gaudette F., Paquin I., Bernstein N., Bouchain G., Vaisburg A., Jin Z., Gillespie J., Wang J., Fournel M., Yan P.T., Trachy-Bourget M.-C., Kalita A., Lu A., Rahil J., MacLeod A.R., Li Z., Besterman J.M., and Delorme D.J. Med. Chem. 51 (2008) 4072
16. Darkin-Rattray S.J., Gurnett A.M., Myers R.W., Dulski P.M., Crumley T.M., Allocco J.J., Cannova C., Meinke P.T., Colletti S.L., Bednarek M.A., Singh S.B., Goetz M.A., Dombrowski A.W., Polishook J.D., and Schmatz D.M. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 13143
17. Frey R.R., Wada C.K., Garland R.B., Curtin M.L., Michaelides M.R., Li J., Pease L.J., Glaser K.B., Marcotte P.A., Bouska J.J., Murphy S.S., and Davidsen S.K. Bioorg. Med. Chem. Lett. 12 (2002) 3443
18. Suzuki T., Kouketsu A., Matsuura A., Kohara A., Ninomiya S.-I., Kohda K., and Miyata N. Bioorg. Med. Chem. Lett. 14 (2004) 3313
19. Suzuki T., Matsuura A., Kouketsu A., Nakagawa H., and Miyata N. Bioorg. Med. Chem. Lett. 15 (2005) 331
20. Itoh Y., Suzuki T., Kouketsu A., Suzuki N., Maeda S., Yoshida M., Nakagawa H., and Miyata N.J. Med. Chem. 50 (2007) 5425
21. Miller T.A., Witter D.J., and Belvedere S.J. Med. Chem. 46 (2003) 5097
22. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Nature 401 (1999) 188
23. Vannini A., Volpari C., Filocamo G., Caroli Casavola E., Brunetti M., Renzoni D., Chakravarty P., Paolini C., De Francesco R., Gallinari P., Steinkuhler C., and Di Marco S. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 15064
24. Somoza J.R., Skene R.J., Katz B.A., Mol C., Ho J.D., Jennings A.J., Luong C., Arvai A., Buggy J.J., Chi E., Tang J., Sang B.-C., Verner E., Wynands R., Leahy E.M., Dougan D.R., Snell G., Navre M., Knuth M.W., McRee D.E., and Tari L.W. Structure 12 (2004) 1325
25. Maryanoff B.E., McComsey D.F., Lee J., Smith-Swintosky V.L., Wang Y., Minor L.K., and Todd M.J.J. Med. Chem. 51 (2008) 2518
26. Winum J.-Y., Temperini C., El Cheikh K., Innocenti A., Vullo D., Ciattini S., Montero J.-L., Scozzafava A., and Supuran C.T.J. Med. Chem. 49 (2006) 7024
27. Winum J.-Y., Scozzafava A., Montero J.-L., and Supuran C.T. Med. Res. Rev. 26 (2006) 767
28. Alker D., Campbell S.F., Cross P.E., Burges R.A., Carter A.J., and Gardiner D.G.J. Med. Chem. 33 (1990) 585
29. Krueger A.C., Madigan D.L., Jiang W.W., Kati W.M., Liu D., Maring C.J., Masse S., McDaniel K.F., Middleton T., Mo H., Molla A., Montgomery D., Pratt J.K., Rockway T.W., Zhang R., and Kempf D.J. Bioorg. Med. Chem. Lett. 16 (2006) 3367
30. Casini A., Winum J.-Y., Montero J.-L., Scozzafava A., and Supuran C.T. Bioorg. Med. Chem. Lett. 13 (2003) 837
31. Espino C.G., Wehn P.M., Chow J., and Du Bois J.J. Am. Chem. Soc. 123 (2001) 6935
32. All experimental details can be found in MethylGene patent application: Smil, D.; Leit, S.; Ajamian, A.; Allan, M.; Chantigny, Y. A.; Déziel, R.; Therrien, E.; Wahhab, A.; Manku, S. International Patent WO 07/143822, 2007.
33. 50) for inhibitors were determined by analyzing dose-response inhibition curves with GraFit.
34. Breslow, R.; Miller, T. A.; Belvedere, S.; Marks, P. A.; Richon, V. M.; Rifkind, R. A. International Patent WO 04/089293, 2004.
35. Vaisburg A., Bernstein N., Frechette S., Allan M., Abou-Khalil E., Leit S., Moradei O., Bouchain G., Wang J., Woo S.H., Fournel M., Yan P.T., Trachy-Bourget M.-C., Kalita A., Beaulieu C., Li Z., MacLeod A.R., Besterman J.M., and Delorme D. Bioorg. Med. Chem. 14 (2004) 283
36. The compounds 4a, 5a, 5b, 7a, 7b, 8, 10, 11, and 12 were not active against HDAC1-3, HDAC8, and HDAC4, HDAC5 and HDAC7.
37. Jones P., Altamura S., Chakravarty P.K., Cecchetti O., De Francesco R., Gallinari P., Ingenito R., Meinke P.T., Petrocchi A., Rowley M., Scarpelli R., Serafini S., and Steinkuhler C. Bioorg. Med. Chem. Lett. 16 (2006) 5948
38. Jones P., Altamura S., De Francesco R., Gonzalez Paz O., Kinzel O., Mesiti G., Monteagudo E., Pescatore G., Rowley M., Verdirame M., and Steinkuhler C.AJ. Med. Chem. 51 (2008) 2350
39. 50 is 0.24 and 0.11 μM on HDAC2 and HDAC3, respectively.
40. Li, Z.; Besterman, J. M.; Bonfils, C. International Patent WO 07/135471 A1, 2007.
41. Fournel M., Bonfils C., Hou Y., Yan P.T., Trachy-Bourget M.-C., Kalita A., Liu J., Lu A.-H., Zhou N.Z., Robert M.-F., Gillespie J., Wang J.J., Ste-Croix H., Rahil J., Lefebvre S., Moradei O., Delorme D., Macleod A.R., Besterman J.M., and Li Z. Mol. Cancer Ther. 7 (2008) 759
42. The whole cell assay was done in cultured Human Embryonic Kidney cells (293T), which were treated with inhibitors for 16 h and then incubated with Boc-Ac-Lys-AMC, a membrane permeable HDAC substrate. After 90 min at 37° C, the reaction was quenched with trypsin and TSA by to a final concentration of 1 mg/mL and 1 μM, respectively. The cells were lysed with 1% NP-40. Fluorescence was read at Ex 360 nm, Em 470 nm, using GeminiXS fluorimeter.
43. The extent of inhibition of total HDAC activity resulting from treatment of 293T cell with the sulfamide inhibitors was comparable to MGCD0103, which was used as control. It is worth noting that the latter inhibitor resulted in about 80-90% decrease of total HDAC activity in intact cells in comparison to SAHA.
44. The cell-based ELISA assays for tubulin and histone acetylation were conducted according to the following protocol: cells were seeded the day before the treatment in 96-well plates. The following day, the cells were incubated for 3 h with the HDAC inhibitors at different concentrations. The cells were fixed on the plate and the appropriated acetylated histone H3 and tubulin antibody was added. The reaction was developed by Amplex Red. The cell number was normalized by Alamar blue.
45. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., and Schreiber S.L. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4389